Sugi Predict

Sugi Predict / Compounds / SCHEMBL6344652

SCHEMBL6344652

SCHEMBL6344652

CCOC(=O)Cc1ncccc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.54
▸ MAPK1 P28482 2/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.48
▸ LMNA P02545 2/20 0.48
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HSD17B10 Q99714 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ PKM P14618 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ TBXAS1 P24557 1/20 0.42
▸ BRD4 O60885 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687369 0.86 MAPT (0.41) MAPTMAPK1CYP1A2CYP3A4CYP2D6
SCHEMBL7010780 0.85 MAPT (0.53) MAPTMAPK1SMN1; SMN2ALDH1A1LMNA
SCHEMBL7882626 0.85 MAPT (0.46) MAPTMAPK1SMN1; SMN2LMNACYP1A2
SCHEMBL4882694 0.84 MAPT (0.52) MAPTMAPK1SMN1; SMN2ALDH1A1LMNA
SCHEMBL31347161 0.84 MAPT (0.52) MAPTMAPK1SMN1; SMN2ALDH1A1LMNA
SCHEMBL10132049 0.84 MAPT (0.52) MAPTMAPK1SMN1; SMN2ALDH1A1LMNA
SCHEMBL5791166 0.84 MAPT (0.52) MAPTMAPK1SMN1; SMN2ALDH1A1LMNA
SCHEMBL932150 0.84 MAPT (0.58) MAPTMAPK1SMN1; SMN2ALDH1A1LMNA
SCHEMBL10131983 0.84 MAPT (0.52) MAPTMAPK1SMN1; SMN2ALDH1A1LMNA
SCHEMBL10515633 0.83 MAPT (0.60) MAPTMAPK1SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3774800-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2024-11-13 — — EP disclosed
US-12116358-B2 Substituted indoles and methods of use thereof Epizyme, Inc. (US) 2024-10-15 — — US disclosed
CN-117865937-A Chiral 2- (beta-amino) pyridine derivative, preparation method and application thereof 成都大学 2024-04-12 — — CN disclosed
US-11702419-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-07-18 — — US disclosed
US-20230075198-A1 SUBSTITUTED INDOLES AND METHODS OF USE THEREOF Epizyme, Inc. 2023-03-09 — — US disclosed
EP-3837240-A1 SUBSTITUTED INDOLES AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2021-06-23 — — EP disclosed
CN-112585119-A Substituted indoles and methods of use thereof EPIZYME股份有限公司 2021-03-30 — — CN disclosed
WO-2020037079-A1 SUBSTITUTED INDOLES AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2020-02-20 — — WO disclosed
WO-2020037079-A1 SUBSTITUTED INDOLES AND METHODS OF USE THEREOF Epizyme, Inc. (US) 2020-02-20 — — WO disclosed
US-20180111948-A1 HERBICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2018-04-26 — — US disclosed
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 — — US disclosed
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-04-05 — — US disclosed
WO-2010026214-A1 PYRAZOLOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-03-11 — — WO disclosed
US-20090275589-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-05 — — US disclosed
CN-101326176-A Pyridazine compound and use thereof SUMITOMO CHEMICAL CO (JP) 2008-12-17 — — CN disclosed
EP-1958946-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 — — EP disclosed
CN-101080409-A 7-amino-6-hetaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and the use thereof for controlling pathogenic fungi BASF AG (DE) 2007-11-28 — — CN disclosed
EP-1028111-B1 AMIDE DERIVATIVES OR SALTS THEREOF YAMANOUCHI PHARMA CO LTD (JP) 2004-05-12 — — EP disclosed
US-6346532-B1 ANTIDIABETIC, ANTILIPEMIC, AND HYPOGLYCEMIC AGENTS; ADRENERGIC STIMULANTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2002-02-12 — — US disclosed
EP-1028111-A1 AMIDE DERIVATIVES OR SALTS THEREOF YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2000-08-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116358-B2 Substituted indoles and methods of use thereof CCNE1, CCNE2, FOXM1 MAPT 1366/4885MAPK1 4310/4885SMN1; SMN2 1177/4885
US-20230075198-A1 SUBSTITUTED INDOLES AND METHODS OF USE THEREOF FOXM1, CCNE2, CCNE1 MAPT 2083/4885MAPK1 4181/4885SMN1; SMN2 1096/4885
US-20180111948-A1 HERBICIDAL COMPOUNDS DDT, DAO, HPD MAPT 3748/4885MAPK1 2140/4885SMN1; SMN2 4544/4885
US-20120083605-A1 PYRIDAZINE COMPOUND AND USE THEREOF PLPBP, PNPO, PDXK MAPT 285/4885MAPK1 1862/4885SMN1; SMN2 2463/4885
US-11702419-B2 Heterocyclic compound and use thereof GRIN2B, GRIN2A, GRIN2C MAPT 216/4885MAPK1 715/4885SMN1; SMN2 3192/4885
US-20090275589-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, PDXK MAPT 285/4885MAPK1 1862/4885SMN1; SMN2 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.